/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

JANUX THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$16.99 0.0788(7.88%) JANX at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 15.52
Highest Today 17.36
Today’s Open 15.86
Prev. Close 15.86
52 Week High 71.71
52 Week Low 15.51
Day’s Range: Low 15.52 High 17.36
52-Week Range: Low 15.51 High 71.71
1 day return -
1 Week return -49.85
1 month return -36.62
3 month return -28.55
6 month return -31.85
1 year return -74.41
3 year return +26.74
5 year return -
10 year return -

Institutional Holdings

RA Capital Management, LLC 18.62

FMR Inc 14.79

HHG PLC 7.42

BlackRock Inc 5.66

Paradigm Biocapital Advisors LP 4.86

Adage Capital Partners Gp LLC 4.20

Fidelity Growth Compy Commingled Pl S 3.67

Vanguard Group Inc 3.64

Point72 Asset Management, L.P. 3.57

T. Rowe Price Associates, Inc. 2.98

Fidelity Growth Company Fund 2.60

Cormorant Asset Management, LLC 2.50

EcoR1 Capital, LLC 2.45

State Street Corp 2.31

Woodline Partners LP 2.07

Citadel Advisors Llc 2.05

Orbimed Advisors, LLC 2.01

Vanguard Total Stock Mkt Idx Inv 1.96

Franklin Resources Inc 1.78

Logos Global Management LP 1.66

iShares Russell 2000 ETF 1.57

Geode Capital Management, LLC 1.50

Bank of America Corp 1.43

Prosight Management, LP 1.42

Fidelity Select Health Care 1.16

Fidelity Small Cap Growth 1.16

US Small-Cap Growth II Equity Comp 1.02

SPDR® S&P Biotech ETF 0.95

T. Rowe Price New Horizons 0.90

Janus Henderson Global Life Sciences 0.86

Janus Henderson Global Life Sciences D 0.86

Janus Henderson Triton D 0.83

Janus Henderson US SMID Cap Growth 0.83

Janus Henderson US SMID Cap Growth MA 0.83

Fidelity Growth Company K6 0.80

Fidelity Advisor Health Care I 0.76

Janus Global Life Science AUSD 0.71

Janus Henderson Glb Life Scn I2 USD 0.70

Fidelity Small Cap Index 0.66

Fidelity Series Growth Company 0.65

Market Status

Strong Buy: 11

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 953.94 M

PB Ratio 2.0997

PE Ratio 0.0

Enterprise Value 1084.11 M

Total Assets 1061.52 M

Volume 5680902

Company Financials

Annual Revenue FY23:8467000 8.5M, FY22:8612000 8.6M, FY21:3637000 3.6M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:8612000 8.6M, FY21:3637000 3.6M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-62600000 -62.6M, FY22:-54154000 -54.2M, FY21:-32559000 -32.6M, FY20:-5255000 -5.3M, FY19:-4237000 -4.2M

Quarterly Revenue Q3/2025:10000000 10.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:439000 0.4M, Q2/2024:8897000 8.9M

Quarterly Profit Q3/2025:9499000 9.5M, Q2/2025:-541000 -0.5M, Q1/2025:-519000 -0.5M, Q3/2024:439000 0.4M, Q2/2024:8391000 8.4M

Quarterly Net worth Q3/2025:-24313000 -24.3M, Q2/2025:-33858000 -33.9M, Q1/2025:-23508000 -23.5M, Q3/2024:-28059000 -28.1M, Q2/2024:-5959000 -6.0M

Fund house & investment objective

Company Information Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 109

Industry Biotechnology

CEO Dr. David Alan Campbell Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow